Acumen Pharmaceuticals, INC. (ABOS) — SEC Filings

Q: What are the key financial highlights for Acumen Pharmaceuticals, INC.?

Key financial highlights for Acumen Pharmaceuticals, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Acumen Pharmaceuticals, INC.?

Key executives at Acumen Pharmaceuticals, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Acumen Pharmaceuticals, INC. stock?

Risk factors for Acumen Pharmaceuticals, INC. (ABOS) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Acumen Pharmaceuticals, INC.?

Forward-looking statements and predictions from Acumen Pharmaceuticals, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Acumen Pharmaceuticals, INC.. Recent EFFECT filing on Apr 2, 2026. AI-decoded analysis of earnings, risk factors, and insider trades

View Acumen Pharmaceuticals, INC. on SEC EDGAR

Overview

Acumen Pharmaceuticals, INC. (ABOS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 2, 2026: Acumen Pharmaceuticals, Inc. filed an EFFECT form on April 2, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 9999999995-26-001054, pertains to Act 33 and has a file number of 333-294649. The effectiveness date is April 1, 2026.

Sentiment Summary

Across 24 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 21 neutral. The dominant filing sentiment for Acumen Pharmaceuticals, INC. is neutral.

Filing Type Overview

Acumen Pharmaceuticals, INC. (ABOS) has filed 1 EFFECT, 1 424B3, 9 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (24)

Acumen Pharmaceuticals SEC Filing Effective — EFFECT · Apr 2, 2026 Risk: low
Acumen Pharmaceuticals, Inc. filed an EFFECT form on April 2, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No.
Acumen Pharmaceuticals Files 424B3 Prospectus — 424B3 · Apr 1, 2026 Risk: low
Acumen Pharmaceuticals, Inc. filed a 424B3 prospectus on April 1, 2026, detailing its offerings. The company, located at 1210-1220 Washington Street, Suite 210,
Acumen Pharma Files 8-K on Financials & Corporate Deck — 8-K · Mar 26, 2026
Acumen Pharmaceuticals, Inc. filed an 8-K on March 26, 2026, disclosing its results of operations and financial condition, along with a corporate presentation.
Acumen's Losses Widen on Soaring R&D as Alzheimer's Trial Progresses — 10-Q · Nov 12, 2025 Risk: high
Acumen Pharmaceuticals, Inc. (ABOS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $96.2 million, up from $6
8-K Filing — 8-K · Nov 10, 2025
10-Q Filing — 10-Q · Aug 12, 2025
Acumen Pharmaceuticals Files 8-K with Material Agreement — 8-K · Jul 15, 2025 Risk: medium
On July 15, 2025, Acumen Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes information regarding Reg
Acumen Pharmaceuticals Files 8-K on Shareholder Vote — 8-K · Jun 5, 2025 Risk: medium
Acumen Pharmaceuticals, Inc. filed an 8-K on June 5, 2025, reporting on matters submitted to a vote of its security holders on June 4, 2025. The filing does not
Acumen Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: low
Acumen Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the biological products sec
Acumen Pharmaceuticals Sets June 4th Annual Meeting — DEF 14A · Apr 23, 2025 Risk: low
Acumen Pharmaceuticals, Inc. filed its definitive proxy statement (DEF 14A) on April 23, 2025, for its annual meeting of stockholders scheduled for June 4, 2025
10-K Filing — 10-K · Mar 27, 2025
Acumen Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Acumen Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first
Acumen Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
Acumen Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first six
Acumen Pharmaceuticals Files 8-K on Security Holder Vote — 8-K · Jun 5, 2024 Risk: low
Acumen Pharmaceuticals, Inc. filed an 8-K on June 5, 2024, reporting on matters submitted to a vote of security holders on June 4, 2024. The filing does not det
Acumen Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: low
Acumen Pharmaceuticals, Inc. (ABOS) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Acumen Pharmaceuticals, Inc. filed a 10-Q report for the perio
Acumen Pharmaceuticals, Inc. Announces Annual Meeting of Stockholders on June 4, 2024 — DEF 14A · Apr 22, 2024 Risk: low
Acumen Pharmaceuticals, Inc. (ABOS) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. Acumen Pharmaceuticals will hold its Annual Meeting of Sto
Acumen Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Mar 26, 2024 Risk: medium
Acumen Pharmaceuticals, Inc. (ABOS) filed a Annual Report (10-K) with the SEC on March 26, 2024. Acumen Pharmaceuticals, Inc. filed its 2023 Form 10-K on March
Acumen Pharmaceuticals Files 8-K on Financials — 8-K · Mar 19, 2024 Risk: low
Acumen Pharmaceuticals, Inc. filed an 8-K on March 19, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
Franklin Resources Takes 5.0% Stake in Acumen Pharma — SC 13G · Feb 6, 2024
Franklin Resources, Inc., a major investment advisor, reported owning 2,427,337 shares of Acumen Pharmaceuticals, Inc. common stock as of December 31, 2023. Thi
Acumen Pharma 8-K: Officer/Director Changes & Comp Arrangements — 8-K · Feb 1, 2024
Acumen Pharmaceuticals, Inc. filed an 8-K on February 1, 2024, reporting on the departure of directors or certain officers, election of directors, appointment o
Murray Jr. Trims Acumen Pharma Stake to 6.0% — SC 13G/A · Jan 24, 2024
James B. Murray, Jr. has filed an amended Schedule 13G/A, indicating his beneficial ownership of 2,681,057 shares of Acumen Pharmaceuticals, Inc. common stock a
Acumen Pharma Files 8-K for Reg FD Disclosure & Exhibits — 8-K · Jan 12, 2024
Acumen Pharmaceuticals, Inc. filed an 8-K on January 12, 2024, to disclose information under Regulation FD and to file financial statements and exhibits. This f
Acumen Pharma to Present at J.P. Morgan Healthcare Conference — 8-K · Jan 8, 2024
Acumen Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose its participation in the 42nd Annual J.P. Morgan Healthcare Conference. During this ev

Risk Profile

Risk Assessment: Of ABOS's 14 recent filings, 1 were flagged as high-risk, 5 as medium-risk, and 8 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Acumen Pharmaceuticals, INC.'s most recent 10-Q filing (Nov 12, 2025):

Revenue: $0
Net Income: -$96.2M
EPS: -$1.59
Debt-to-Equity: 0.53
Cash Position: $46.8M
Operating Margin: N/A
Total Assets: $142.2M
Total Debt: $49.0M

Key Executives

Daniel O'Connell
Nathan Fountain, M.D.

Industry Context

The biopharmaceutical industry, particularly in the Alzheimer's disease space, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Acumen face intense competition from both established pharmaceutical giants and emerging biotech firms, all vying for breakthroughs in a challenging therapeutic area.

Top Tags

corporate-governance (4) · 10-Q (4) · Biotechnology (3) · pharmaceuticals (3) · financials (3) · Acumen Pharmaceuticals (3) · sec-filing (2) · filing (2) · regulation-fd (2) · shareholder-vote (2)

Key Numbers

Effectiveness Date: 2026-04-01 — The date the registration statement became effective.
Filing Acceptance Date: 2026-04-02 — The date the SEC accepted the filing.
Net Loss: $96.2M — Increased from $65.2M in 9M 2024, a 47.5% rise, indicating widening losses.
Research and Development Expenses: $84.4M — Increased from $59.2M in 9M 2024, a 42.5% rise, reflecting significant investment in sabirnetug.
Accumulated Deficit: $421.3M — Increased from $325.1M at Dec 31, 2024, highlighting sustained unprofitability.
Cash and Cash Equivalents: $46.8M — As of Sep 30, 2025, up from $35.6M at Dec 31, 2024, but overall liquidity is down.
Total Marketable Securities: $89.2M — Decreased from $195.9M at Dec 31, 2024, indicating significant cash utilization.
Working Capital: $110.2M — Decreased from $150.7M at Dec 31, 2024, signaling reduced short-term liquidity.
Common Shares Outstanding: 60,573,425 — As of Nov 7, 2025, indicating potential for future dilution with additional financing.
Net Loss Per Share (Q3 2025): $0.44 — Compared to $0.50 in Q3 2024, showing a slight per-share improvement despite higher net loss due to share count.
SEC File Number: 001-40551 — Identifies the company's filings with the SEC.
IRS Employer Identification No.: 36-4108129 — Company's tax identification number.
Reporting Period End Date: 2025-03-31 — Indicates the end of the financial quarter being reported.
Filing Date: 2025-05-13 — The date the report was officially submitted to the SEC.
Accession Number: 0001576885-25-000057 — Unique identifier for this SEC filing

Related Companies

ACUM

Frequently Asked Questions

What are the latest SEC filings for Acumen Pharmaceuticals, INC. (ABOS)?

Acumen Pharmaceuticals, INC. has 24 recent SEC filings from Jan 2024 to Apr 2026, including 9 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ABOS filings?

Across 24 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 21 neutral. The dominant sentiment is neutral.

Where can I find Acumen Pharmaceuticals, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Acumen Pharmaceuticals, INC. (ABOS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Acumen Pharmaceuticals, INC.?

Key financial highlights from Acumen Pharmaceuticals, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for ABOS?

The investment thesis for ABOS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Acumen Pharmaceuticals, INC.?

Key executives identified across Acumen Pharmaceuticals, INC.'s filings include Daniel O'Connell, Nathan Fountain, M.D..

What are the main risk factors for Acumen Pharmaceuticals, INC. stock?

Of ABOS's 14 assessed filings, 1 were flagged high-risk, 5 medium-risk, and 8 low-risk.

What are recent predictions and forward guidance from Acumen Pharmaceuticals, INC.?

Forward guidance and predictions for Acumen Pharmaceuticals, INC. are extracted from SEC filings as they are enriched.